GREENFIELD, IN / ACCESS Newswire / February 25, 2025 / Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has ...
Elanco Animal Health Incorporated (NYSE:ELAN) reported fourth-quarter revenue of $1.02 billion, a decrease of 1% on a ...
Elanco has struck an agreement to distribute a vaccine that may protect cattle for up to 12 months against bird flu ...
Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health’s Fourth Quarter 2024 Earnings Conference ...
We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...
Elanco Animal Health (NYSE:ELAN) stock falls as the company reports mixed Q4 2024 results, and sets 2025 outlook below consensus due to forex headwinds. Read more here.
Stifel analyst Jonathan Block lowered the firm’s price target on Elanco (ELAN) to $15 from $16 and keeps a Buy rating on the shares. While the ...
Barclays lowered the firm’s price target on Elanco (ELAN) to $19 from $20 and keeps an Overweight rating on the shares. The firm sees a “solid ...
Elanco Animal Health will commercialize an avian flu vaccine for dairy cattle after reaching an agreement with Medgene.
Elanco's Q4 revenue reached $1.02 billion, topping estimates, but EPS missed forecasts. 2025 guidance lags consensus as currency headwinds pose a $110 million challenge.
Elanco Animal Health narrowed its fourth-quarter loss despite lower sales, but its forecast for the current quarter and full year came in below Wall Street's estimates.
Zoetis also has an H5N1 vaccine, for which it received a conditional license in 2016 and a contract award for the USDA’s ...